Standing Order
All companies

Biotech

Vertex Pharmaceuticals Incorporated

VRTXNASDAQdiversified
Market cap$131B
Conviction5/ 5
HQBoston, MA, USA
View full dashboard

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Price · 1Y

$515.02

+15.6%

Thesis

Vertex runs a near-monopoly in cystic fibrosis with the Trikafta/Kaftrio franchise generating roughly $10B+ in annual revenue, funding one of biotech's most disciplined R&D engines. That cash flow is now backing a diversification beyond CF into gene editing and non-opioid pain, which transforms the story from a single-disease specialist into a multi-franchise platform.

Casgevy, partnered with CRISPR Therapeutics, is the first FDA-approved CRISPR/Cas9 therapy and addresses sickle cell disease and transfusion-dependent beta thalassemia. Journavx (suzetrigine), approved January 2025, is a first-in-class NaV1.8 inhibitor for moderate-to-severe acute pain, opening a non-opioid category the company can own commercially.

Catalysts

  • Casgevy patient activations and authorized treatment center ramp
  • Journavx adoption in post-surgical settings and label expansion into chronic pain
  • Next-gen CF triple combo (vanzacaftor) cannibalization economics
  • Pipeline readouts in APOL1-mediated kidney disease and type 1 diabetes cell therapy

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

  • Nov 19
    Trial initiationClinicalTrials.gov

    Phase 3b trial NCT07890909 of Povetacicept autoinjector vs Sibeprenlimab syringe begins recruiting.

  • Nov 18
    Trial initiationClinicalTrials.gov

    Vertex initiates Phase 2/3 trial of povetacicept in primary membranous nephropathy (NCT07204275, recruiting).

  • Nov 17
    Trial readoutClinicalTrials.gov

    Vertex completes Phase 4 single-arm trial NCT06887959 of Suzetrigine for acute post-surgical pain.

  • Nov 17
    Trial readoutClinicalTrials.gov

    Vertex updates NCT06696443 Phase 3 long-term safety/efficacy trial of suzetrigine in painful DPN; status ACTIVE_NOT_RECRUITING as of 2026-11-17.

  • Nov 16
    Trial readoutClinicalTrials.gov

    Completed Phase 4 single-arm study NCT06887972 of suzetrigine for acute post-surgical pain

  • Nov 2
    Financial resultsSEC

    Vertex Pharmaceuticals 8-K (items 2.02, 9.01) reports results of operations.

  • Oct 30
    OtherClinicalTrials.gov

    Phase 3 trial NCT06696443 for long-term safety/effectiveness of suzetrigine in painful diabetic peripheral neuropathy updated to active, not recruiting.

  • Oct 30
    Trial initiationClinicalTrials.gov

    Vertex initiates phase 2/3 trial (NCT07204275) of povetacicept in primary membranous nephropathy; recruiting status as of 2026-10-30.

Not financial advice — research and opinion only. Disclosures